Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from...
Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target fro...
Guggenheim analyst Debjit Chattopadhyay maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target ...
Mizuho analyst Uy Ear upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Outperform and raises the price target fro...
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevi...
Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $21...
